After Promising Coronavirus Vaccine Data, Is Pfizer a Buy?
Shares of Pfizer (NYSE: PFE) have been on the move since the company announced promising clinical trial results for BNT162b2, a coronavirus vaccine candidate the company is developing in partnership with BioNTech (NASDAQ: BNTX).
It looks like the significant investment Pfizer made to address the COVID-19 pandemic was a well-placed bet. Following the first interim analysis of a huge phase 3 trial, BNT162b2 appears 90% effective at preventing healthy people from developing COVID-19.
Image source: Getty Images.
Source Fool.com
